In a recent opinion published in JAMA, health policy researchers reviewed the advantages and disadvantages of prior authorization in Medicare Advantage (MA) to identify key areas that need improvement.
Prior authorization in Medicare Advantage (MA), used by payers and detested by providers, can be improved with a few policy changes, according to researchers in a recent opinion piece in JAMA.
MA covers more than 48% of Medicare beneficiaries, with 99% of MA plans requiring PA for medical services. Traditional fee-for-service Medicare has also implemented PA for a small number of services, such as home health and specific surgical procedures.
PA aims to reduce unnecessary health care spending or steer providers towards high-value care. However, it can also delay or deny needed care. It is also a factor in physician burnout; one survey found that 88% of 1004 physicians reported the “burden associated with prior authorization requirements was high or extremely high.”
Current efforts at reform include a bill passed by the House of Representatives last month and proposals to force the use of guidelines.
The Improving Seniors' Timely Access to Care Act would require CMS to report how often they use PA as well as the rate of approvals and denials, and would require HHS to set up a real time decision process for all services that are typically approved. The bill would also include an electronic PA processing system that health care organizations have wanted for years.
In their Viewpoint, researchers from the University of Colorado and John Hopkins University called for 3 other ideas:
In a statement, lead author Kelly E. Anderson, PhD, MPP, assistant professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, addressed the need for improvements when utilizing PA.
“There’s currently a lot of discussion about modernizing and monitoring the use of PA in Medicare to serve patients and the whole health care system better,” said Anderson. “We hope by describing the theoretical goals of prior authorization and where implementation is failing to meet these goals and the needs of Medicare beneficiaries, we can provide decision-makers a comprehensive accounting of the system and opportunities to improve it.”
For patients needing intensive treatments or major surgical procedures, delays can significantly affect the outcome of lifesaving treatments. In addition, denial of proper treatment may lead patients to seek out alternative treatments or procedures that are less effective, more risky and more costly long-term.
A 2018 investigation by the HHS' Office of Inspector General found that 56% of 140 MA audited contracts had inappropriately denied by PA requests and 45% of MA contracts had sent denial letters with missing information, including how to appeal the denial.
A follow up investigation in 2022 found that 13% of 12,273 PA requests were inappropriately denied. In addition, 75% of approximately 863,000 denial appeals were later approved.
For patients seeking out intensive treatments or major surgical procedures such as chemotherapy or limb amputation, delays of just several days can significantly affect the outcome of lifesaving treatments. denial of proper treatment may lead patients to seek out alternative treatments or procedures that are less affective, more risky and more costly long-term.
“By improving transparency and accountability of the process, prior authorization can better function as a tool to improve high-value care for Medicare beneficiaries,” researchers concluded.
Reference
Anderson KE, Darden M, Jain A. Improving prior authorization in Medicare advantage. JAMA. Published online October 3, 2022. doi:10.1001/jama.2022.17732
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More
2 Commerce Drive
Cranbury, NJ 08512